• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response to: 'Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered'.

作者信息

Novembre Elio, Gelsomino Mariannita, Liotti Lucia, Barni Simona, Mori Francesca, Giovannini Mattia, Mastrorilli Carla, Pecoraro Luca, Saretta Francesca, Castagnoli Riccardo, Arasi Stefania, Caminiti Lucia, Klain Angela, Del Giudice Michele Miraglia

机构信息

Department of Health Sciences, University of Florence, Florence, 50139, Italy.

Department of Life Sciences and Public Health, Pediatric Allergy Unit, University Foundation Policlinico Gemelli IRCCS Catholic University of the Sacred Heart, Rome, Italy.

出版信息

Ital J Pediatr. 2024 Nov 10;50(1):233. doi: 10.1186/s13052-024-01815-6.

DOI:10.1186/s13052-024-01815-6
PMID:39521965
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11550513/
Abstract
摘要

相似文献

1
Response to: 'Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered'.回应：“应将口服免疫疗法失败视为严重过敏反应的一个风险因素，并考虑使用奥马珠单抗治疗”。
Ital J Pediatr. 2024 Nov 10;50(1):233. doi: 10.1186/s13052-024-01815-6.
2
Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered.口服免疫治疗失败应被视为致命性过敏反应的一个风险因素，并考虑使用奥马珠单抗治疗。
Ital J Pediatr. 2024 Nov 9;50(1):232. doi: 10.1186/s13052-024-01814-7.
3
Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.联合抗IgE单克隆抗体与口服免疫疗法治疗食物过敏
Clin Rev Allergy Immunol. 2022 Feb;62(1):216-231. doi: 10.1007/s12016-021-08902-0. Epub 2021 Sep 22.
4
Use of omalizumab in the treatment of food allergy and anaphylaxis.奥马珠单抗在食物过敏和过敏反应治疗中的应用。
Curr Allergy Asthma Rep. 2013 Feb;13(1):78-84. doi: 10.1007/s11882-012-0316-x.
5
Real life study of the use of omalizumab for pediatric patients with multiple food allergies.奥马珠单抗用于患有多种食物过敏的儿科患者的真实生活研究。
Allergol Immunopathol (Madr). 2021 Mar 1;49(2):15-22. doi: 10.15586/aei.v49i2.36. eCollection 2021.
6
Oral immunotherapy in severe cow's milk allergic patients treated with omalizumab: Real life survey from a Spanish registry.口服免疫疗法在接受奥马珠单抗治疗的重度牛奶过敏患者中的应用：来自西班牙登记处的真实生活调查。
Pediatr Allergy Immunol. 2021 Aug;32(6):1287-1295. doi: 10.1111/pai.13517. Epub 2021 Apr 27.
7
A practical guide for implementing omalizumab therapy for food allergy.食物过敏奥马珠单抗治疗实施实用指南。
J Allergy Clin Immunol. 2024 Jun;153(6):1510-1517. doi: 10.1016/j.jaci.2024.03.019. Epub 2024 Apr 9.
8
Oral immunotherapy for peanut allergy: multipractice experience with epinephrine-treated reactions.口服免疫疗法治疗花生过敏：接受肾上腺素治疗的过敏反应的多实践经验。
J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):91-6. doi: 10.1016/j.jaip.2013.10.001.
9
Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.奥马珠单抗可确保系统性肥大细胞增多症患者在蜂毒免疫疗法（VIT）诱导的过敏反应后对VIT的耐受性。
Allergol Select. 2021 Mar 11;5:128-132. doi: 10.5414/ALX02196E. eCollection 2021.
10
The Effectiveness of Oral Immunotherapy in Patients with Sesame Anaphylaxis using Omalizumab.使用奥马珠单抗对芝麻过敏患者进行口服免疫治疗的有效性
Clin Med Res. 2022 Aug 23;20(3):125-32. doi: 10.3121/cmr.2022.1730.

本文引用的文献

1
Fatal food anaphylaxis in adults and children.成人和儿童致命食物过敏。
Ital J Pediatr. 2024 Mar 5;50(1):40. doi: 10.1186/s13052-024-01608-x.
2
Life-threatening anaphylaxis in children with cow's milk allergy during oral immunotherapy and after treatment failure.儿童牛奶过敏患者在口服免疫治疗期间及治疗失败后出现危及生命的过敏反应。
Immun Inflamm Dis. 2022 Apr;10(4):e607. doi: 10.1002/iid3.607.
3
Omalizumab effectiveness in patients with a previously failed oral immunotherapy for severe milk allergy.奥马珠单抗治疗口服免疫治疗失败的重度牛奶过敏患者的疗效。
Immun Inflamm Dis. 2022 Jan;10(1):117-120. doi: 10.1002/iid3.542. Epub 2021 Oct 8.